AI assistant
BIOMARIN PHARMACEUTICAL INC — Director's Dealing 2016
May 10, 2016
30583_dirs_2016-05-10_7ccde12c-f54f-4ec7-b004-97b720dabcfc.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK: 0001048477
Period of Report: 2016-04-29
Reporting Person: Davis George Eric (EVP, General Counsel)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2016-04-29 | Common Stock | A | 414 | $51.264 | Acquired | 91894 | Direct |
| 2016-05-06 | Common Stock | F | 1696 | $80.80 | Disposed | 90198 | Direct |
| 2016-05-09 | Common Stock | S | 10000 | $84.5532 | Disposed | 80198 | Direct |
| 2016-05-10 | Common Stock | S | 4658 | $86.3202 | Disposed | 75540 | Direct |
Footnotes
F1: The reporting person is reporting the purchase of shares of the issuer's Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of November 1, 2015, to April 30, 2016.
F2: The price in column 4 is the weighted average. The price actually ranged from $84.50 to $84.72. The reporting person shall provide to the issuer, and security holder of the issuer, or the SEC staff upon request, information regarding the number of shares sold at each price within the range.
F3: The price in column 4 is the weighted average. The price actually ranged from $86.3140 to $86.3210. The reporting person shall provide to the issuer, and security holder of the issuer, or the SEC staff upon request, information regarding the number of shares sold at each price within the range.